Tagged with Global

Global The timely and equitable provision of treatment and prevention tools is just one part of the ongoing fight against HIV. Local, national, regional, and international authorities – many of which still labour under misguided preconceptions about people living with HIV – need to come together to effectively buttress the provision…

Global Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many patients can still enjoy long and largely healthy lives. This, however, is contingent on them having access to the full…

Global In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step up, and the establishment of some vital institutional structures in the first decade of the millennium, access is up, while…

Global As pharma navigates issues ranging from the US Inflation Reduction Act to new EU pharmaceutical legislation, and the impact of global unrest on supply chains, the industry is experiencing other shifts as reflected in Pharma Exec’s 2024 Top 50 Companies. Based on 2023 drug revenue performance from global drug makers,…

USA AbbVie, for only the second time in its history, has a new CEO. Having been led by Richard A. Gonzalez since its inception in 2013, the organization has named former president and chief operating officer Robert A. Michael as its new leader. As he takes on the role this month,…

USA The Promising Pathways Act 2.0 is a newly proposed bill that aims to expedite and streamline approval pathways for rare disease therapies in the US. The Act is, however, facing a number of challenges in terms of implementation. The sponsors of these niche therapies tend to be small and medium-sized…

Global 35 years after the specific mechanisms and structure of the human immunodeficiency virus were first identified, the world is still waiting for a vaccine against HIV. Several late-stage candidates have failed in this time, leading to most of the major pharma companies exiting HIV vaccine research. Some new early-stage approaches…

Global Brendan Shaw paints a concerning picture of global health priorities post-pandemic, highlighting the need for renewed focus and investment in healthcare systems to prevent further backsliding.   “There isn’t a financing gap. There is just money that is not moving towards the right things. There’s plenty of money out there”…

Global Writing in the June 2024 edition of ISPOR’s Value in Health journal, Nancy J. Devlin, PhD, Michael F. Drummond, MCom, DPhil, and C. Daniel Mullins, PhD look back on the history of QALYs in cost-effectiveness analysis and policy decision making, and why the backlash against QALYs in the United States…

Global As Big Pharma makes evermore declarations on its sustainability credentials, who are the industry’s most sustainable companies? With wildlife under severe threat from biopharmaceutical run-off, which companies are truly dedicated to change? Which are truly dedicated to equitable pay structures and promoting diversity, equity and inclusion? To answer these questions,…

USA A public health initiative said to have saved over 25 million lives, the US President’s Emergency Plan for AIDS Relief (PEPFAR) has had an enormous impact on the fight against HIV/AIDS through providing HIV treatment, prevention, and education. Since its inception in 2003 PEPFAR has largely enjoyed bipartisan support within…

Global One of the doyens of European biotech is stepping back from general management. Jean-Paul Clozel founded rare disease focused Actelion along with his wife Martine Clozel in 1997, a company that went on to become publicly traded and launch three blockbuster drugs. The Clozels then sold up to J&J for…